Drug
LPM3770164 clinical trials
Also written LY03015.
Keep track of what changes. Save the LPM3770164 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses LPM3770164 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaRecruitingPhase 1/2Luye Pharma Group Ltd.NCT06731868Written as LPM3770164 sustained release tablet 5 mg
- Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release TabletsCompletedPhase 1Luye Pharma Group Ltd.NCT06474650Written as LPM3770164 sustained release tablet
- Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy SubjectsCompletedPhase 1Luye Pharma Group Ltd.NCT06216054Written as LPM3770164 sustained release tablet
- A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy SubjectsCompletedPhase 1Luye Pharma Group Ltd.NCT05238701Written as LPM3770164 sustained release tablet